Edgar Filing: KAKKIS EMIL D - Form 4

KAKKIS EN Form 4 December 24 FORN Check th if no long subject to Section 1 Form 4 co Form 5 obligation may com <i>See</i> Instr 1(b).	0, 2007 A UNITED states box ger o 16. or Filed pur tinue.	IENT OF suant to S a) of the F	Was CHAN ection 14 Public Ut	shingt GES SEC 6(a) o fility H	ion, IN I UR f the Hold	D.C. 205 BENEFI ITIES e Securiti	549 CIA es Ez pany	L OWN	OMMISSION NERSHIP OF e Act of 1934, 1935 or Section 0	OMB Number: Expires: Estimated a burden hour response		
(Print or Type]	Responses)											
KAKKIS EMIL D Symbol BIOM				Issuer Name and Ticker or Trading bol DMARIN PHARMACEUTICAL C [BMRN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mon				6. Date of Earliest Transaction Month/Day/Year) 10/31/2007					Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
(City)	(State)	(Zip)	Tabl	e I - No	on-D	erivative S	Securi	ties Acqu	Person uired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	ned 3. 4. Securities Acquired n Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8) (A) or				quired l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Direct Beneficial (D) or Ownership Indirect (I) (Instr. 4) (Instr. 4)			
Common Stock	10/31/2007(1)			Р	V		A	\$ 6.919	96,164	D		
Common Stock	12/17/2007			G	V	10,000	D	\$0	86,164	D		
Common Stock									4,654	Ι	Shares held by spouse	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: KAKKIS EMIL D - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL 105 DIGITAL DRIVE NOVATO, CA 94949	INC.		Chief Medical Officer					
Signatures								
/s/ G. Eric Davis, Attorney-in-Fact	12/19/2007							

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to the Employee Stock Purchase Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.